HK1136214A1 - Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124- - Google Patents

Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124-

Info

Publication number
HK1136214A1
HK1136214A1 HK10103079.6A HK10103079A HK1136214A1 HK 1136214 A1 HK1136214 A1 HK 1136214A1 HK 10103079 A HK10103079 A HK 10103079A HK 1136214 A1 HK1136214 A1 HK 1136214A1
Authority
HK
Hong Kong
Prior art keywords
oxadiazole
dosing
methods
nonsense mutation
orally active
Prior art date
Application number
HK10103079.6A
Other languages
English (en)
Chinese (zh)
Inventor
薩米特‧海拉華特
藍登‧米勒
Original Assignee
醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39102963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1136214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 醫療公司 filed Critical 醫療公司
Publication of HK1136214A1 publication Critical patent/HK1136214A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
HK10103079.6A 2006-10-12 2010-03-24 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124- HK1136214A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85145006P 2006-10-12 2006-10-12
PCT/US2007/021921 WO2008045566A1 (en) 2006-10-12 2007-10-11 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

Publications (1)

Publication Number Publication Date
HK1136214A1 true HK1136214A1 (en) 2010-06-25

Family

ID=39102963

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10103079.6A HK1136214A1 (en) 2006-10-12 2010-03-24 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124-
HK12111647.0A HK1170690A1 (zh) 2006-10-12 2012-11-16 給用口服活性 -噁二唑進行無義突變抑制治療的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12111647.0A HK1170690A1 (zh) 2006-10-12 2012-11-16 給用口服活性 -噁二唑進行無義突變抑制治療的方法

Country Status (24)

Country Link
US (7) US9226919B2 (sv)
EP (2) EP2460520B1 (sv)
JP (4) JP2010506840A (sv)
KR (4) KR20160128468A (sv)
CN (2) CN101553226B (sv)
AU (1) AU2007308067B2 (sv)
BR (2) BRPI0719276A2 (sv)
CA (1) CA2675518C (sv)
CL (1) CL2007002923A1 (sv)
DK (1) DK2073805T3 (sv)
ES (1) ES2538359T3 (sv)
HK (2) HK1136214A1 (sv)
HR (1) HRP20150590T1 (sv)
IL (2) IL198147A (sv)
MX (1) MX2009003909A (sv)
NO (1) NO342061B1 (sv)
PE (4) PE20080982A1 (sv)
PL (1) PL2073805T3 (sv)
PT (1) PT2073805E (sv)
RS (1) RS54025B1 (sv)
RU (1) RU2462247C2 (sv)
SI (1) SI2073805T1 (sv)
TW (1) TWI405570B (sv)
WO (1) WO2008045566A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2910551B1 (en) 2003-04-11 2017-02-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
IN2014CN04406A (sv) * 2006-03-30 2015-09-04 Ptc Therapeutics Inc
BRPI0719276A2 (pt) 2006-10-12 2014-04-29 Ptc Therapeutics Inc Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN106455571A (zh) * 2014-03-06 2017-02-22 Ptc医疗公司 1,2,4‑噁二唑苯甲酸的药物组合物和盐
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
AR106530A1 (es) 2015-10-30 2018-01-24 Ptc Therapeutics Inc Métodos para tratar epilepsia
AR113780A1 (es) 2017-10-19 2020-06-10 Cipla Usa Inc Síntesis de análogos de aminoglicósidos antibacterianos
EP3713934B1 (en) 2017-11-23 2022-04-13 Universita' degli Studi di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
KR102378381B1 (ko) * 2021-08-23 2022-03-24 라이보텍(주) 넌센스-매개 mRNA 분해를 억제하기 위한 화합물
EP4295849A1 (en) * 2021-02-16 2023-12-27 Ribotech Co., Ltd. Compound for suppressing nonsense-mediated mrna decay
WO2022241030A1 (en) * 2021-05-11 2022-11-17 Regenxbio Inc. Treatment of duchenne muscular dystrophy and combinations thereof
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
US20040132726A1 (en) * 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP2910551B1 (en) * 2003-04-11 2017-02-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
CN1905856A (zh) * 2003-12-23 2007-01-31 阿尔扎公司 用于增加受控递送的药物组合物的溶解度的方法和剂型
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US20070010553A1 (en) * 2005-07-01 2007-01-11 Astrazeneca Ab New use
US7678922B2 (en) 2006-09-08 2010-03-16 Ptc Therapeutics, Inc. Processes for the preparation of 1,2,4-oxadiazole benzoic acids
UA99600C2 (en) 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
BRPI0719276A2 (pt) 2006-10-12 2014-04-29 Ptc Therapeutics Inc Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.

Also Published As

Publication number Publication date
IL236519A0 (en) 2015-02-26
PE20160947A1 (es) 2016-09-26
CA2675518C (en) 2017-11-14
CN101553226B (zh) 2015-05-13
EP2460520A1 (en) 2012-06-06
US20180140583A1 (en) 2018-05-24
AU2007308067A1 (en) 2008-04-17
CA2675518A1 (en) 2008-04-17
CN103211766B (zh) 2015-03-11
BR122019020961B1 (pt) 2021-03-09
HRP20150590T1 (hr) 2015-07-03
EP2460520B1 (en) 2015-09-30
IL198147A0 (en) 2009-12-24
HK1170690A1 (zh) 2013-03-08
IL198147A (en) 2016-02-29
CL2007002923A1 (es) 2008-06-06
AU2007308067B2 (en) 2013-05-30
JP2010506840A (ja) 2010-03-04
EP2073805B1 (en) 2015-03-04
TWI405570B (zh) 2013-08-21
KR20170100072A (ko) 2017-09-01
KR20090074231A (ko) 2009-07-06
KR20160128468A (ko) 2016-11-07
CN103211766A (zh) 2013-07-24
US10849885B2 (en) 2020-12-01
US9737513B2 (en) 2017-08-22
US9226919B2 (en) 2016-01-05
WO2008045566B1 (en) 2008-06-19
DK2073805T3 (da) 2015-06-15
BR122019020961B8 (pt) 2021-07-27
JP2017081946A (ja) 2017-05-18
SI2073805T1 (sl) 2015-10-30
IL236519A (en) 2017-03-30
RS54025B1 (en) 2015-10-30
US20190099405A1 (en) 2019-04-04
CN101553226A (zh) 2009-10-07
US9522137B2 (en) 2016-12-20
KR101758341B1 (ko) 2017-07-14
PE20120670A1 (es) 2012-06-01
PL2073805T3 (pl) 2015-08-31
PT2073805E (pt) 2015-07-13
US20160101087A1 (en) 2016-04-14
US20210038572A1 (en) 2021-02-11
PE20080982A1 (es) 2008-07-19
JP2016029078A (ja) 2016-03-03
PE20212245A1 (es) 2021-11-24
ES2538359T3 (es) 2015-06-19
JP6333227B2 (ja) 2018-05-30
NO342061B1 (no) 2018-03-19
MX2009003909A (es) 2009-05-25
JP2014058533A (ja) 2014-04-03
JP6129713B2 (ja) 2017-05-17
KR20150064244A (ko) 2015-06-10
RU2462247C2 (ru) 2012-09-27
BRPI0719276A2 (pt) 2014-04-29
US20080114039A1 (en) 2008-05-15
NO20091826L (no) 2009-07-08
US20170049752A1 (en) 2017-02-23
US10172836B2 (en) 2019-01-08
RU2009117590A (ru) 2010-11-20
EP2073805A1 (en) 2009-07-01
US9877952B2 (en) 2018-01-30
WO2008045566A1 (en) 2008-04-17
US20170304275A1 (en) 2017-10-26
TW200820968A (en) 2008-05-16

Similar Documents

Publication Publication Date Title
IL236519A0 (en) Dosing methods of active 4,2,1-oxadiazole in oral administration to suppress non-sense mutation
IL236518A0 (en) Compounds of active 4,2,1-oxadiazole for oral administration for the treatment of suppression of nonsense mutation
IL251539A0 (en) Single pharmaceutical dosage form
IL182459A0 (en) Compounds for nonsense suppression, and methods for their use
PL2058020T3 (pl) Urządzenie do podawania leków
EP1885414A4 (en) DEVICE FOR MEDICAMENT ADMINISTRATION
EP1885415A4 (en) ADMINISTRATOR OF DOSAGE DOSES
HRP20130344T1 (en) Buprenorphine wafer for drug substitution therapy
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
SI2464337T2 (sl) Formulacija tablete N-(2,4-bis(1,1-dimetiletil)-5-hidroksifenil)-1,4-dihidro-4-oksokinolin -3-karboksamida za uporabo v zdravljenju cistične fibroze
IL222557A (en) A compound for use in treating mutant disorders has ruled
ZA201003963B (en) Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
ZA200707513B (en) Dispenser for delivering medicament
IL193094A0 (en) Improved antitumoral treatments
SG138565A1 (en) Punctal plugs for the delivery of active agents
GB0616794D0 (en) Solid dosage form
IL199239A0 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
SG138564A1 (en) Punctal plugs for the delivery of active agents
ZA200809554B (en) 3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides
AU2006904946A0 (en) Improved floor treatment machine
GB0612429D0 (en) Vibrating gaming chair
AU2006905385A0 (en) Personal Care Vending Machine
AU2006906311A0 (en) Improved Gaming Token
WO2009032558A3 (en) Preparation of ziprasidone hydrochloride monohydrate